MedTrace Logo

Liposomal Bupivacaine To Control Post-Operative Pain Following BMG

NCT03720223 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2021-10-01

No results posted yet for this study

Summary

This is a single blinded-randomized controlled trial that recruit male patients for substitution urethroplasty using buccal mucosal graft. The study investigators aim to assess the efficacy and safety of liposomal bupivacaine injection to the buccal graft harvest site on post-operative main score, morphine equivalence requirement and oral morbidities.

Conditions

  • Urethral Stricture

Interventions

DRUG

Liposomal Bupivacaine

20ml of Liposomal Bupivacaine 1.3% (13.3mg/mL)

Sponsors & Collaborators

  • Urology of Virginia

    lead OTHER

Principal Investigators

  • Kurt McCammon, MD FACS · Eastern Virginia Medical School- Urology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-20
Primary Completion
2017-10-31
Completion
2017-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03720223 on ClinicalTrials.gov